Anúncio
Anúncio

KPRX

KPRX logo

Kiora Pharmaceuticals, Inc. Common Stock

2.16
USD
Patrocinado
-0.03
-1.33%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

2.13

-0.02
-0.97%

Relatórios de Lucros KPRX

Rácio de surpresa positiva

KPRX separação 24 de 38 últimas estimativas.

63%

Próximo Relatório

Data do Próximo Relatório
23 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.53M
/
-$0.68
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/
-6900.00%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
-34.62%

Kiora Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On 07 de nov. de 2025, KPRX reported earnings of 0.01 USD per share (EPS) for Q3 25, beating the estimate of -0.74 USD, resulting in a 101.33% surprise. Revenue reached --, compared to an expected 765.00 mil, with a -100.00% difference. The market reacted with a +0.43% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analistas forecast an EPS of -0.68 USD, with revenue projected to reach 1.53 milhão USD, implying an diminuir of -6900.00% EPS, and -- of --% in Revenue from the last quarter.
FAQ
For Q3 2025, Kiora Pharmaceuticals, Inc. Common Stock reported EPS of $0.01, beating estimates by 101.33%, and revenue of $0.00, -100% below expectations.
The stock price moved up 0.43%, changed from $2.32 before the earnings release to $2.33 the day after.
The next earning report is scheduled for 23 de mar. de 2026.
Based on 3 analistas, Kiora Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.68 and revenue of $1.53M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio